Shares of Hims & Hers Health (HIMS) plunged Friday after the 澳洲幸运5官方开奖结果体彩网:Food & Drug Administration said a shortage of the active ingredient in Novo Nordisk’s (NVO) Wegovy and Ozempic has been resolved.

Semaglutide injections, which have become a popular treatment option for weight loss as well as Type 2 diabetes, have been considered to be in a shortage since 2022.

This could affect Hims & Hers, which makes compounded versions of 澳洲幸运5官方开奖结果体彩网:weight-loss drugs by combining the key ingredient in the patented version with other drugs. This is legal thanks to an FDA rule known as 503B, which allows companies to 澳洲幸运5官方开奖结果体彩网:mass-produce compounded drugs when the originals are hard to obtain.

The FDA said it does not 🌠intend to take action against 503B drug compounders for 90 days, or until May 22, “to avoid un👍necessary disruption to patient treatment.”

Hims Says It Will Monitor for Future Shortages

Hims & Hers 澳洲幸运5官方开奖结果体彩网:Chief Executive Officer Andrew Dudum said Friday in a post on X that the company "will continue to offer access to personalized treatments as allowed by law," adding that the company is "closely monitoring potential future shortages."

This comes after the FDA said in October that Eli Lilly weight-loss treatments Mounjaro and Zepbound (which use the active ingredient tirzepatide, rather than semaglutide) were 澳洲幸运5官方开奖结果体彩网:no longer on its list of drugs in short supply.

Hims’ stock fell more than 23% by Friday afternoon, wiping out gains earlier this week after the company announced plans to roll out 澳洲幸运5官方开奖结果体彩网:at-home blood testing over the next year. Shares of Novo Nordisk gained more than 5%.

CORRECTION—Feb. 25, 2025: This article has been corrected since it was first published to reflect Wegovy is produced by Novo Nordisk.